About AGENTA Therapeutics
AGENTA Therapeutics is a biotech company developing novel immunotherapies to treat cancer and immune dysfunctions. AGENTA’s technology and pipeline are focused on monoclonal antibody products as immune checkpoint inhibitors for the activation of Natural Killer (NK) cells and T cells to treat cancer.
Meet the Founder
Dr. J. Joseph Kim, Founder & CEO
- Former founder and CEO of INOVIO Pharmaceuticals (NASDAQ:INO).
- Took INOVIO public and grew it from a start up into a public biotech with >350 FTEs and a peak market capitalization of $5.3 billion in 2020.
- Recruited and built high-performing teams with strong corporate culture.
- Fundraised >$1.0 billion in capital at INOVIO Pharmaceuticals and VGX Pharmaceuticals.
- Directed $1.2 billion major product out-licensing deals with large pharma companies (AstraZeneca and Roche).
- Brought in >$350 million in non-dilutive funding through grants/contracts.
- Advanced new compounds tested via clinical stages for FDA and regulatory agency approval.
Management Team
Dr. Jean Boyer Vice President, R&D
Dr. Ildiko Csiki Chief Medical Consultant
Dr. Ildiko Csiki Chief Medical Consultant
- Former VP, Analytical Science & Immunology of INOVIO Pharm.
- Former VP, R&D of Imunon Pharma.
- Former Associate Research Professor at the University of Pennsylvania
- Led multiple immunology and analytical programs for Phase I through Phase III clinical trials for infectious diseases and oncology
Dr. Ildiko Csiki Chief Medical Consultant
Dr. Ildiko Csiki Chief Medical Consultant
Dr. Ildiko Csiki Chief Medical Consultant
- Former Chief Medical Officer of Sensei Biotherapeutics
- Former Chief Commercial R&D Officer at City of Hope and Vice President at INOVIO
- Held clinical development lead roles at Merck responsible for KEYTRUDA® development in multiple indications
Dr. Samuel Broder Senior Advisor
Dr. Ildiko Csiki Chief Medical Consultant
Dr. Samuel Broder Senior Advisor
- Former Director of National Cancer Institute
- Oversaw the development of numerous anti-cancer and anti-viral therapeutic agents
- Has served on the boards of numerous successful biotech companies